Resources

Gain key insights quickly: engage with disease and treatment resources.

Graphic Abstracts

Overt HE

Rifaximin for the Reduction of Risk of Overt HE Recurrence

Bass NM, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362(12):1071-1081.

View

IBS-D

Two-Week Course of Rifaximin for Patients with IBS-D

Pimentel M, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364(1):22-32.

View

Two-Week Repeat Rifaximin Course in Initial IBS-D Responders

Lembo A, et al. Repeat treatment with rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome. Gastroenterology. 2016;151(6):1113-1121.

View

Videos

IBS-D

Efficacy of rifaximin on bloating in patients with diarrhea-predominant irritable bowel syndrome (IBS-D): a pooled analysis of three phase 3, randomized, placebo-controlled trials

Lacy BE. United European Gastroenterology (UEG) Week 2020, October 11-13, 2020, Virtual.

View

IBS-D


AASLD = American Association for the Study of Liver Diseases; AGA = American Gastroenterological Association; HE = hepatic encephalopathy; IBS = irritable bowel syndrome; IFFGD = International Foundation for Gastrointestinal Disorders; NIDDK = National Institute of Diabetes and Digestive and Kidney Diseases; NIH = National Institutes of Health.

Search

*Required field.

Select a product*

Select

Select a therapeutic area*

Select

Enter keyword(s)